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OBJECTIVES We sought to determine the predictive ability of troponin I (TnI) in a heterogeneous group
of patients with chest pain admitted from the emergency department (ED) for exclusion of
myocardial infarction (MI).
BACKGROUND Previous studies in high-risk patients demonstrated that troponin elevations are associated
with increased cardiac events. Little information is available on its predictive ability in more
heterogeneous, lower risk patients.
METHODS Consecutive patients admitted from the ED for possible MI underwent serial myocardial
marker sampling of TnI and creatine kinase, CK-MB over an 8-h period. Patients with ST
segment elevation were excluded. End points included MI, death, significant complications
(e.g., cardiac or respiratory arrest, intra-aortic balloon pump, pulmonary artery catheter or
pacemaker placement, revascularization or inotropic infusion) and significant disease.
RESULTS Events occurred in 513 (27%) of the 1,929 patients evaluated: MI in 175 (9.1%) and death
in 34 (1.8%); an additional 248 patients (13%) without MI had complications, and 323 (17%)
without MI had significant disease. Sensitivity of TnI for MI was high (96%). Patients
without MI who were TnI-positive were more likely to have complications (43% vs. 12%) or
significant disease (41% vs. 17%) as compared with those who were TnI-negative; however,
the sensitivity of TnI for these two end points was low (14% and 21%, respectively). Predictive
values were unchanged after excluding patients with ischemic electrocardiograms.
CONCLUSIONS Troponin I had a high sensitivity for MI when used as part of a rapid rule-in protocol;
however, the sensitivity for other end points was low. Use of TnI alone failed to identify the
majority of patients who had either significant disease or complications. (J Am Coll Cardiol
2000;36:1818–23) © 2000 by the American College of Cardiology
Patients presenting with chest pain or other symptoms
suggestive of myocardial ischemia represent a spectrum of
diagnoses from musculoskeletal pain to acute myocardial
infarction (MI). In patients who have ST segment elevation
consistent with myocardial injury, MI is highly likely (1,2).
However, these patients constitute only a minority of those
presenting with chest pain. Accurate early identification of
MI or myocardial ischemia in the remaining patients is
difficult, resulting in the hospital admission of many patients
who are ultimately found to have nonischemic causes for
their symptoms (1).
See page 1824
Cardiac troponin T (TnT) and I (TnI) can identify
patients who have minimal amounts of myocardial necrosis
(3,4). Patients who have troponin elevations are at increased
risk for adverse cardiac events, even in the absence of MI
identified by traditional criteria (3,5). Most previous inves-
tigations examining the predictive ability of troponin were
limited by inclusion of only high risk patients (3,6–8), the
majority of whom had MI (7,8), used only the initial sample
(7,8) or prolonged sampling for up to 24 to 48 h (3,9,10),
thus limiting our knowledge of these markers’ performance
when used in rapid rule-out protocols. Therefore, we
examined the relation between cardiac events and TnI in a
large, heterogeneous nonselected patient group undergoing
a rapid MI diagnostic pathway.
METHODS
The chest pain protocol used at our institution has been
described in detail previously (11). All patients who present
to the Medical College of Virginia Hospitals’ Emergency
Department (ED) with symptoms suggestive of myocardial
ischemia undergo prompt clinical evaluation by ED house
staff and attending physicians. After the initial evaluation,
patients thought to be at high risk (ischemic electrocardio-
graphic [ECG] changes or typical symptoms in patients
with known coronary disease) are admitted directly to the
Coronary Care Unit (CCU), whereas those at low to
moderate risk for acute coronary syndromes undergo further
risk stratification using early rest myocardial perfusion
imaging (11). Moderate risk patients are admitted, whereas
low risk patients undergo perfusion imaging from the ED
and are discharged and scheduled for outpatient stress
testing if the images are negative. All monitoring and data
collection were done as part of an ongoing quality-
improvement process and were not considered to need
approval from the Committee on the Conduct of Human
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Research. From June 1996 through May 11, 1998, 2,194
consecutive patients were admitted to the CCU from the
ED for suspected MI. Patients with ST segment elevation
meeting criteria for fibrinolytic therapy were excluded (n 5
125), as MI was highly likely. An additional 124 patients
did not have an 8-h TnI sample, and 16 patients left against
medical advice before marker sampling was completed,
leaving 1,929 patients. Only the initial hospital admission
was included for patients admitted more than once. All
patients underwent serial testing for creatine kinase,
CK-MB by mass assay and total CK at 0, 3, 6 and 8 h after
presentation. Troponin I was sampled at the time of
admission and at 8 h. Sampling was continued at 6- to 8-h
intervals in patients diagnosed with MI or those who had
recurrent or continuing symptoms until a diagnosis was
made. Decisions regarding further diagnostic evaluation
were made by the attending cardiologist in the CCU.
The CK-MB assay (Behring Diagnostics, Boston, Mas-
sachusetts) used in this study has been described in detail
previously (12). Total serum CK activity (Vitros, Johnson &
Johnson, Rochester, New York) was determined using
N-acetylcysteine activation without pretreatment. Troponin
I was measured using the Opus Magnum Analyzer (Behring
Diagnostics). Centrifuged plasma was filtered before anal-
ysis using 0.2-mm sterile filters fitted to 3-ml Becton
Dickinson (Franklin Lakes, New Jersey) syringes. The lower
limit for detectability for this assay is 0.5 ng/ml, and the
manufacturers’ suggested diagnostic value for MI is
2.0 ng/ml.
Diagnosis of MI required symptoms consistent with
myocardial ischemia with a CK-MB level $8.0 ng/ml and
a relative index $4 ([CK-MB 3 100]/total CK). The initial
ECG from the ED was interpreted by a cardiologist who
had no knowledge of the clinical variables, TnI results and
outcomes. The ECGs showing transient ST segment ele-
vation, ST segment depression $1 mm or T-wave inversion
$2 mm were considered consistent with ischemia. All other
ECGs were considered nonischemic. Patients undergoing
coronary angiography had it performed using the Judkin’s
technique, with views of the coronary arteries obtained in
multiple projections. Significant coronary artery disease was
defined as $50% stenosis of the left main coronary artery or
$70% stenosis in a major coronary artery, its branches or a
bypass graft. Cardiac death was defined as death secondary
to MI or arrhythmia, or an unexpected death of unknown
cause.
Cardiac end points included 1) MI within one week; 2)
cardiac death within five weeks; 3) significant disease
demonstrated on coronary angiography within five weeks; 4)
significant complications, defined as revascularization (cor-
onary artery bypass graft surgery [CABG] or percutaneous
transluminal coronary angioplasty [PTCA]) within five
weeks; or 5) any of the following which occurred during
hospital admission: cardiac or respiratory arrest, intubation,
insertion of an intra-aortic balloon pump, second- or
third-degree heart block requiring placement of a trans-
venous pacemaker, ventricular tachycardia requiring treat-
ment with an intravenous antiarrhythmic drug or cardiover-
sion, ventricular fibrillation or the need for inotropic
support. For patients who had more than one event, only
the initial one was used for analysis. Predictive values for the
non-MI end points were calculated after exclusion of the
patients with MI.
Relative risks (13) were calculated as described previously.
The results were compared using the Student t test for




CAD (n 5 517)
No D/MI/Sig.








Age $60 years 840 (44%) 251 (49%)¶ 589 (41%) 116 (47%) 631 (42%) 145 (45%)
Male 937 (49%) 282 (55%)¶ 655 (46%) 132 (53%) 708 (47%) 172 (53%)\
Typical chest pain* 1,113 (58%) 317 (61%) 796 (56%) 152 (61%) 863 (57%) 207 (64%)\
Hypertension 1,264 (66%) 358 (69%)\ 906 (64%) 182 (73%)¶ 980 (65%) 239 (74%)#
Diabetes 609 (32%) 190 (37%)¶ 419 (30%) 106 (43%)# 457 (30%) 135 (42%)#
Tobacco use† 803 (42%) 229 (44%) 574 (41%) 102 (41%) 621 (41%) 144 (45%)
Family history of CAD‡ 495 (26%) 132 (26%) 363 (26%) 70 (28%) 386 (26%) 90 (28%)
Elevated cholesterol§ 968 (50%) 346 (67%)# 622 (44%) 153 (62%)# 701 (47%) 229 (71%)#
ECG evidence of previous MI 474 (25%) 157 (30%)# 317 (22%) 79 (32%)¶ 355 (24%) 114 (35%)#
Previous revascularization 464 (24%) 165 (32%)# 299 (21%) 91 (39%)# 337 (22%) 125 (39%)#
* Symptoms described as chest pressure, tightness, burning, heaviness, squeezing, crushing, indigestion or shortness of breath, and symptoms similar to previous angina or
infarction. †Current or tobacco use within two years. ‡First-degree male relative ,55 years old or female ,65 years old with myocardial infarction or revascularization. §Use
of a cholesterol-lowering agent or total cholesterol .200 mg/dl. \p , 0.05, ¶p , 0.01 and #p , 0.001, as compared with variable without that outcome. Data are presented
as the number (%) of patients.
CAD 5 coronary artery disease; D 5 death; ECG 5 electrocardiographic; MI 5 myocardial infarction; Sig. 5 significant.
Abbreviations and Acronyms
CABG 5 coronary artery bypass graft surgery
CCU 5 coronary care unit
CK 5 creatine kinase
ECG 5 electrocardiogram or electrocardiographic
ED 5 emergency department
MI 5 myocardial infarction
PTCA 5 percutaneous transluminal coronary angioplasty
TnI 5 troponin I
TnT 5 troponin T
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continuous variables and the chi-square test for dichoto-
mous variables. A p value #0.05 was considered significant.
Multivariate analysis was performed using stepwise logistic
regression (SAS, version 6.11). Candidate variables in-
cluded clinical variables (Table 1), as well as an ischemic
ECG and a TnI level $1.0 ng/ml. Variables with a p value
,0.10 were then entered into the logistic regression model.
RESULTS
The demographic data of the 1,929 patients who formed the
study cohort are shown in Table 1. End points occurred in
513 patients and included death in 34 (1.8%) and MI in 175
(9.1%). Coronary angiography was performed in 534 pa-
tients without MI, 323 of whom had significant coronary
disease. A total of 248 patients without MI had at least one
significant complication, which included death in 20, revas-
cularization in 193 (PTCA in 143 and CABG in 50),
intravenous pressor support in 23, intubation in 19, pulmo-
nary artery catheterization in 10, transvenous pacemaker
placement in 6, intra-aortic balloon pump in 4 and ventric-
ular tachycardia or fibrillation in 6.
A receiver-operating characteristic curve, derived using
the end point of MI, demonstrated that the optimal cutoff
value for MI was 1.0 ng/ml (Fig. 1), which was used for all
later analyses.
A total of 288 patients (15%) had at least one positive
TnI. Troponin I was positive in 175 (91%) of the 195 pa-
tients who had a MI or who died, and in 168 (96%) of the
175 patients with MI alone. The initial TnI was positive in
62 of the patients (35%) who had MI. Troponin I was
positive in 52 patients (21%) who had significant compli-
cations and in 45 patients (14%) who had significant
coronary disease. Predictive values and relative risks for TnI
are shown in Table 2. Patients with a positive TnI were
significantly more likely to have a MI, significant compli-
cations or significant disease (Fig. 2).
Troponin I was negative in seven patients diagnosed with
MI. Four of the patients had a peak CK-MB level ,10 ng/ml.
A fifth patient had a peak CK-MB level of 30 ng/ml, but
repeated TnI samples were all ,0.5 ng/ml. Subsequent
coronary angiography demonstrated no significant coronary
disease. There was a minimal change from the first to the
fourth CK-MB measurement in these five patients, suggest-
ing that the elevations resulted from a noncardiac source. In
the sixth patient, CK-MB was not elevated until the third
sample; TnI 12 h after presentation was 3.0 ng/ml. In the
seventh patient, CK-MB was not elevated until the fourth
sample; TnI 10 h after presentation was 4.6 ng/ml. Tropo-
nin I was also negative in nine patients who had cardiac
death without MI (mean duration from hospital admission
to death 18 6 12 days). Troponin I was positive in 59 patients
who did not have one of the end points. The mean value was
3.4 6 4.9 ng/ml (median 1.8 ng/ml [range 1.0 to 29]).
Ischemic ECG changes were present in 213 patients
(11%). Of these, 51 patients died or had a MI, 41 had
significant complications and 53 had significant coronary
disease. The predictive values for an ischemic ECG are
shown in Table 3. Patients who had an ischemic ECG were
significantly more likely to have adverse events (Fig. 3).
The sensitivity of TnI was significantly higher than that
Figure 1. Receiver-operating characteristic curve using MI as the end
point. A troponin I value of 1.0 ng/ml was the optimal cutoff value.
Table 2. Predictive Accuracy of Troponin I Value $ 1.0 ng/ml for Predicting Outcomes in All Patients and After Excluding Patients
With Ischemic Electrocardiograms
Outcome
All Patients Nonischemic ECG Only
Sensitivity (%) Specificity (%) RR Sensitivity (%) Specificity (%) RR
MI 96 (92–98) 93 (92–94) 330 (110–710) 97 (92–99) 94 (93–95) 450 (110–1,250)
MI or death 92 (87–95) 92 (87–95) 160 (77–276) 90 (84–94) 94 (93–95) 150 (68–270)
MI/D or significant CAD 43 (39–48) 95 (94–96) 15 (11–21) 40 (35–45) 95 (94–96) 14 (10–20)
Significant complications 20 (15–25) 96 (95–97) 6.7 (4.4–10) 19 (14–25) 95 (94–96) 5.5 (3.5–8.4)
Significant CAD 14 (11–18) 95 (94–96) 3.3 (2.2–4.9) 12 (8.8–17) 95 (94–96) 3.0 (1.9–4.7)
Numbers in parentheses indicate 95% confidence intervals.
RR 5 relative risk; other abbreviations as in Table 1.
Figure 2. Outcomes in patients with (open bars) and without (solid bars)
TnI elevations. Comp 5 significant complications; D 5 death; M 5
myocardial infarction; Sig 5 significant coronary disease.
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of an ischemic ECG for most end points (Fig. 4). However,
this was primarily a result of the high sensitivity of TnI for
MI; sensitivities were not significantly different in patients
who had complications or who had significant disease.
The predictive ability of TnI was reexamined after ex-
cluding the 213 patients with ischemic ECGs. Myocardial
infarction or death occurred in 144 patients (8.4%), signif-
icant complications in 208 (12%) and significant disease in
269 (16%). The predictive ability of TnI was unchanged
(Table 2).
Multivariate analysis demonstrated that a positive TnI
value was the most important predictor of the combination
of MI, death and significant coronary disease (Table 4). A
positive TnI value was also the most important multivariate
predictor of significant complications (Table 5) and of
significant coronary disease (Table 6).
DISCUSSION
In the largest study to date to examine the predictive value
of either TnT or TnI, we found that TnI had a high
sensitivity for identifying patients who had MI, when it was
used as part of an 8-h rapid diagnostic protocol. The
sensitivities of TnI for the different end points were un-
changed after excluding patients with an ischemic ECG.
However, the sensitivity for identifying patients who had
significant complications or significant coronary disease was
low and was similar to the presence of ischemic ECG
changes.
Troponin I in patients with MI. The sensitivity of TnI
was high for identifying patients with MI, when it was used
in this rapid 8-h diagnostic pathway. Although one study
reported a relatively low sensitivity (9), most studies using
prolonged troponin sampling have reported sensitivities
similar to the current one (7,8,10). Reasons for variations
include differences in underlying risk and frequency of MI,
timing of presentation, time course of sampling and use of
different assays and cutoff values. Inclusion of patients who
have ST segment elevation can overestimate early sensitivity
because of the larger infarct size and more rapid marker rise
(14). Sensitivity is also affected by the choice of cutoff value.
In contrast to studies that used the manufacturers’ suggested
cutoff values, we used receiver-operator characteristic curve
analysis to determine the optimal cutoff value.
Although sensitivity was high, some patients with MI did
not have TnI elevations. Because peak troponin values in
patients with MI are proportional to infarct size, they will be
lower in patients with small MIs (15). Sensitivity is affected
by the choice of the reference standard, which, if not
perfect, results in some patients without necrosis being
incorrectly diagnosed as having MI (16–18). This likely
occurred in some of the patients who had minor CK-MB
elevations without TnI elevations.
Finally, if sampling occurs early after the onset of necro-
sis, troponin values may be undetectable, as was seen in two
patients with MI having late TnI elevations. It has been
proposed that troponin sampling could be used as the only
marker for identifying patients with myocardial necrosis
(19–21). Our data indicate that if a rapid diagnostic
rule-out pathway is used, inclusion of another marker that is
released earlier after the onset of necrosis, such as CK-MB
(22), is necessary to ensure that patients with MI are not
misidentified.
Figure 3. Outcomes in patients with (open bars) and without (solid bars)
an ischemic ECG. Comp 5 significant complications; D 5 death; M 5
myocardial infarction; Sig 5 significant coronary disease.
Figure 4. Comparison of the sensitivity of positive troponin I (open bars)
and the ECG (solid bars) for predicting end points. Comp 5 significant
complications; D 5 death; M 5 myocardial infarction; Sig 5 significant
coronary disease.
Table 4. Multivariate Predictors of Myocardial Infarction,
Death or Significant Disease
Predictor p Value Odds Ratio
Elevated troponin I ,0.0001 17.0 (12.3–23.6)
Elevated cholesterol ,0.0001 2.59 (2.01–3.33)
Ischemic electrocardiogram ,0.0001 2.50 (1.76–3.55)
Previous revascularization ,0.0001 1.78 (1.36–2.31)
Male 0.0002 1.59 (1.25–2.03)
Numbers in parentheses indicate 95% confidence intervals.
Table 3. Predictive Accuracy of an Ischemic Electrocardiogram
for Predicting Outcomes
Outcome Sensitivity (%) Specificity (%) RR
MI 27 (21–35) 91 (89–92) 3.6 (2.4–5.3)
MI or death 27 (21–34) 91 (89–92) 3.5 (2.4–5.0)
MI, death or
significant CAD
21 (17–24) 92 (91–94) 3.0 (2.3–4.1)
Significant
complications
17 (13–24) 94 (93–95) 3.1 (2.4–4.6)
Significant CAD 17 (13–22) 92 (91–94) 2.4 (1.6–3.4)
Numbers in parentheses indicate 95% confidence intervals.
Abbreviations as in Tables 1 and 2.
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Troponin I in patients without MI. The prevalence of
patients without MI who had a positive TnI value was only
9.6%, which is lower than some (3,6–8) but not all
(9,19,23) prevalences in previous studies. Initial studies were
conducted in patients enrolled in clinical protocols (3,6–8)
that included only high risk patients, with an associated
higher incidence of troponin positivity. Studies performed
in more heterogeneous groups of patients with chest pain
have found a proportion of patients with troponin elevations
similar to that of the current one (9,10,19,20).
Early identification of patients with acute coronary syn-
dromes allows initiation of appropriate therapy, which can
improve outcomes. Patients without MI who had TnI
elevations were a high risk group, as the majority had
complications or significant coronary disease. Importantly,
excluding patients with ischemic ECG changes did not alter
the predictive accuracy of TnI. This is significant, as this
patient group presents the greatest diagnostic challenge for
excluding myocardial ischemia.
Although TnI was an independent predictor of the
non-MI cardiac events, the sensitivity was low, indicating
that most patients with these end points did not have TnI
elevations. Therefore, the absence of TnI elevations identi-
fies a lower risk, but not necessarily a low risk, patient group.
Previous studies have also found limitations of troponin for
identifying high risk patients. These include little to no
difference in the incidence of recurrent ischemia (6), revas-
cularization (6,24–26) or the extent of coronary disease
(8,27,28) in patients with and without troponin elevations.
Although it has been suggested that patients with negative
troponin values within 6 h of symptom onset could be safely
discharged home (19,20), the low sensitivity and positive
predictive value of TnI found in this study, as well the
results of others (9,10), indicate that this strategy would
misidentify many patients who are at risk of complications.
Our study differs from previous investigations in several
ways. This is the largest study reported to examine the
predictive ability of troponin in a heterogeneous group of
patients with chest pain; therefore, it better defines the test’s
diagnostic accuracy. We excluded patients with ST segment
elevation, because this is a high risk group in whom the
initial decision for reperfusion therapy is based only on
clinical variables. Although they provide prognostic infor-
mation, biochemical markers are not indicated for initial
triage and treatment decisions in these patients. We ana-
lyzed the predictive ability of TnI after excluding patients
with ischemic ECGs, because these are the patients in
whom a diagnosis is in doubt and in whom markers play a
critical role.
Study limitations. The TnI results were available to the
clinicians caring for the patient and may have affected
decisions for further care, such as the decision to perform
coronary angiography. However, this would not affect the
sensitivity for MI or for other complications. We used
revascularization as an end point. Although there is a
potential selection bias, all patients had rest angina in
combination with significant coronary disease on the coro-
nary angiogram. Despite its potential limitations, revascu-
larization has been used as an end point in other studies of
unstable angina (9,24,27,29). The incidence of revascular-
ization in the current study was not excessive and was
similar to (30) or lower than (3,6,29) the revascularization
rates in previous studies. Use of other complications as end
points is limited by the low overall risk in heterogeneous
groups of patients (9,10). We did not include patients who
were discharged from the ED after the initial evaluation.
However, because our protocol requires rest perfusion im-
aging to be negative in low risk patients before they are
discharged, the risk of serious complications is very low
(,1%) (11).
Conclusions. We found that TnI had a high sensitivity for
identifying patients who had a MI, when it was used in a
rapid diagnostic protocol. Excluding patients with an isch-
emic ECG did not change the sensitivities of TnI for the
different end points. However, the sensitivity for identifying
patients who had significant complications or significant
coronary disease was low and failed to identify the majority
of non-MI end points.
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